Lenalidomide Overcomes Poor Prognosis Conferred by del13q and t(4;14) but Not del17p13 in Multiple Myeloma: Results of the Canadian MM016 Trial.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Blood

• Publication date

  2007-11-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V110.11.3597.3597
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high‐risk multiple myeloma in Asian patients

  2018cites this paper
• Novel agents have a significant impact on survival of patients with multiple myeloma

  2015cites this paper
• Множественная миелома (лечение рецидивов и рефрактерных форм): обзор литературы и собственные данные. Часть III

  2014cites this paper
• Dexamethasone plus lenalidomide in treatment of multiple myeloma

  2011cites this paper
• Mechanizmy działania leków immunomodulujących w szpiczaku plazmocytowym

  2011cites this paper
• Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation.

  2011cites this paper
• Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs

  2010cites this paper
• Gain of 1q21 is an unfavorable genetic prognostic factor for multiple myeloma patients treated with high-dose chemotherapy.

  2010cites this paper
• Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma

  2009cites this paper
• Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts

  2009cites this paper
• From cell biology to therapy: lenalidomide in relapsed/refractory multiple myeloma

  2009cites this paper
• Immunomodulatory agents in oncology

  2009cites this paper
• High-Throughput Molecular Profiling: Insights into Myeloma Pathogenesis and Clinical Outcome

  2009cites this paper
• Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy

  2009cites this paper
• Clinical significance of cyclin D1, fibroblast growth factor receptor 3, and p53 immunohistochemistry in plasma cell myeloma treated with a thalidomide-based regimen.

  2009cites this paper
• Treatment of newly diagnosed myeloma

  2009cites this paper
• Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

  2009cites this paper
• Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone.

  2009cites this paper
• Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy

  2009cites this paper
• Treatment of relapsed/refractory multiple myeloma.

  2009cites this paper
• Multiple myeloma: biology, standard therapy, and transplant therapy.

  2009cites this paper
• New Insights into the Molecular Basis of Multiple Myeloma Pathogenesis and Prognosis

  2009cites this paper
• Redefining Risk Using Cytogenetic Changes

  2009cites this paper
• Treatment of multiple myeloma with immunomodulatory drugs – thalidomide, lenalidomide and pomalidomide

  2009cites this paper
• Congress report: 49th Annual Meeting of the American Society of Haematology, Georgia World Congress Center, December 8–11 2007, Atlanta, Georgia

  2008cites this paper
• Treatment of relapsed and refractory myeloma

  2008cites this paper
• Emerging Therapies for Multiple Myeloma

  2006cites this paper